Access the full text.
Sign up today, get DeepDyve free for 14 days.
Rothman DJ, Arch Intern Med (2011)
From disclosure to transparency: the use of company payment data [published online ahead of print September 13, 2010]., 171
S. Chimonas, Zachary Frosch, D. Rothman (2011)
From disclosure to transparency: the use of company payment data.Archives of internal medicine, 171 1
I read with interest—rather shock—the study by Chimonas and coworkers1 about the lack of disclosure by researchers. I have one simple question: How can a profession as dignified as medicine allow this kind of behavior? This and related behavior is beyond unethical, is embarrassing to the medical profession, and should simply not be tolerated. As telling as the findings of this study are, there is an even more insidious issue at play here. Conflict is almost certainly more pervasive than believed; even if someone discloses a financial relationship, that certainly does not mean that a conflict does not exist or guarantee that the data published are not biased. These studies are still hitting the presses, and potentially biased information is still published. It seems that authors themselves will not police this. Thus, journals must develop a systematic methodology for controlling conflicts. The authors raise the possibility that “disclosure” information could somehow be used. Yes, journals should ask for full disclosure of all monetary and grant payments. But, far more is needed from editors, journals, and the academic community. For example, conflicts might seriously be taken into account in the decision to publish. Furthermore, if an author is found to have failed to disclose a financial relationship, their ability to publish (anywhere) should be severely restricted. It seems unlikely that the sort of unsavory behavior identified by Chimonas and coworkers1 will change until the current system is transformed. Correspondence: Dr Rockey, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8887 (don.rockey@utsouthwestern.edu). Financial Disclosure: Dr Rockey has received a research grant from Sucampo Pharmaceuticals and is participating in research studies with Hyperion Therapeutics, Olympus America Inc, and Alnylam Pharmaceuticals. References 1. Chimonas SFrosch ZRothman DJ From disclosure to transparency: the use of company payment data [published online ahead of print September 13, 2010]. Arch Intern Med 2011;171 (1) 81- 86PubMed10.1001/archinternmed.2010.341Google Scholar
Archives of Internal Medicine – American Medical Association
Published: Jan 10, 2011
Keywords: disclosure
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.